PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle during GLP-1 therapy. The report highlights growing industry interest, strategic acquisitions by major pharma companies like Eli Lilly and AstraZeneca, and the potential for combination therapies to enhance patient results. This emerging category could reshape obesity treatment by improving body composition and creating new intellectual property and partnership opportunities. The report signals a shift from just weight loss to quality of weight loss in obesity therapeutics.
Eli Lilly announced plans to file for FDA approval of retatrutide, a new weight-loss drug, following phase 3 trials where participants lost an average of nearly 56 pounds over 80 weeks. The drug targets multiple hormones affecting appetite and metabo...
Eli Lilly announced it will file for regulatory approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027 after successful late-stage trials. The drug showed significant weight loss—up to 22.6% of body weight—and improve...
Investors seeking passive income should focus on dividend ETFs that prioritize sustainable payouts and long-term growth rather than just high yields. The Schwab U.S. Dividend Equity ETF (SCHD), Vanguard Dividend Appreciation ETF (VIG), and iShares Co...
